fenofibrate

Overview

Fenofibrate is a synthetic lipid-modifying agent in the fibrate class, used clinically to lower elevated triglycerides and, in some settings, to improve mixed dyslipidemia. It is a prodrug that is converted in vivo to fenofibric acid, the active metabolite. Its principal pharmacologic action is activation of peroxisome proliferator-activated receptor alpha (PPAR-α), which regulates genes involved in fatty acid oxidation, lipoprotein metabolism, and triglyceride clearance.

Beyond its established therapeutic role, fenofibrate continues to be studied in broader biomedical contexts because of its effects on lipid handling, inflammation, and cellular stress pathways. In recent research, it has also appeared in computational drug-repurposing workflows and environmental monitoring studies, reflecting both its clinical relevance and its persistence as a pharmaceutically active compound in the environment.

Focus of Latest Publications

Recent investigations of fenofibrate have expanded beyond traditional dyslipidemia management into novel therapeutic contexts. Computational and experimental studies have identified fenofibrate's potential efficacy in sepsis-induced acute kidney injury, where it demonstrated anti-inflammatory and anti-senescence effects through interaction with senescence-related proteins including CDKN1C, BCL2, and SMAD3 in both in vivo and in vitro models. Additionally, fenofibrate has been evaluated as add-on therapy for primary biliary cholangitis patients exhibiting suboptimal response to ursodeoxycholic acid, with preliminary evidence of biochemical benefit, though long-term survival outcomes remain under investigation. In the obstetric setting, fenofibrate showed efficacy for managing severe hypertriglyceridemia-induced pancreatitis in pregnancy, maintaining triglyceride levels below 13 mmol/L at 200 mg/day when used as maintenance therapy following acute plasma exchange interventions.

Parallel advances in pharmaceutical formulation science have characterized fenofibrate's behavior in modern delivery systems. Nanoemulsion studies using quantitative NMR spectroscopy revealed that fenofibrate exhibits proportional redistribution into large oil droplets during carrier destabilization, reflecting its relatively high lipid-phase solubility compared to other poorly water-soluble drugs. Method development work has focused on robust analytical quantitation of fenofibrate in gel-matrix sustained-release tablet formulations designed to prevent dose-dumping phenomena. Sensory evaluation studies, however, demonstrated that incorporation of fenofibrate into lipid nanocarriers paradoxically increased bitter-taste perception compared to the drug powder alone, suggesting that drug localization at oil-water interfaces may intensify rather than mask taste properties.

Comparative pharmacological analysis has positioned fenofibrate within the evolving fibrate drug class, with newer selective peroxisome proliferator-activated receptor α modulators such as pemafibrate demonstrating superior tolerability profiles at substantially lower doses. Environmental surveillance data indicate that while fenofibrate exhibits relatively low aquatic occurrence in subtropical river basins, it carries a comparatively high potential ecotoxicity impact score relative to its measured concentrations, warranting consideration in pharmaceutical risk assessment frameworks.

Key Publications

NEWJul Data Mining of the Japanese Adverse Drug Event Report Database and Animal Experiments for Assessment of Risks Associated With Pemafibrate. (In vivo (Athens, Greece), 2026, PMID 42379788): "Compared to fenofibrate, a conventional fibrate, pemafibrate exerts a triglyceride-lowering effect at 1/500 of the dose, and the incidence rate of adverse drug reactions is one-ninth at these doses."
NEWJun Biomedical publication details. (PubMed Database, 2026, PMID 42260710)
Jun Combining bioinformatics and machine learning to analyze and validate sepsis-related cell senescence genes and potential drugs. (Renal failure, 2026, PMID 42219284): "The binding energies of fenofibrate with these target proteins were less than -5.0 kcal/mol."
Jul Fenofibrate add-on therapy improves transplant-free survival in primary biliary cholangitis patients. (European journal of gastroenterology & hepatology, 2026, PMID 42214018): "Fenofibrate has shown biochemical benefit in primary biliary cholangitis (PBC) patients with a suboptimal response to ursodeoxycholic acid (UDCA), but its long-term efficacy on survival remains unknown."
May A 35-Year-Old Woman With Recurrent Hypertriglyceridemia-Induced Pancreatitis in Pregnancy Managed With Fenofibrate and Plasmapheresis. (The American journal of case reports, 2026, PMID 42204798): "Early TPE followed by continuous fenofibrate safely mitigates triglyceride rebound, prevents pancreatic injury, and prolongs pregnancy to term."
Jun Formulation of poorly water-soluble drugs in lipid nanocarriers: a suitable approach for taste masking or bitter-taste enhancing? (International journal of pharmaceutics, 2026, PMID 42150644): "...embedding the three poorly water-soluble model drugs fenofibrate, simvastatin, and naproxen in nanoemulsions led to newly created or increased bitterness compared to the non-formulated drug powders."
May Development and validation of a QbD-integrated sensitive RP-HPLC method for quantitation of fenofibrate: an application in quality control. (Analytical methods : advancing methods and applications, 2026, PMID 42093465): "The present study aims to develop and validate a robust, sensitive HPLC method for the estimation of fenofibrate in a gel-matrix sustained-release tablet formulation designed to prevent alcohol-induced dose dumping."
Jun Occurrence, spatiotemporal distribution, and potential toxicity analysis of pharmaceutically active compounds in the Pearl River Basin. (Environmental pollution (Barking, Essex : 1987), 2026, PMID 42025674): "Notably, some PhACs (fenofibrate and paroxetine) exhibited comparatively low environmental concentrations but achieved relatively high potential ecotoxicity impact scores."